Protara Therapeutics, Inc. (NASDAQ: TARA) reported Q4 EPS of ($0.37), $0.02 worse than the analyst estimate of ($0.35).

For earnings history and earnings-related data on Protara Therapeutics, Inc. (TARA) click here.